Business Context and Reporting Period
This Form 8-K filing by Altimmune, Inc. is dated June 18, 2018. The report addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
On June 18, 2018, Derace Schaffer, M.D., informed the Board of Directors that he will not stand for reelection at the Company's 2018 Annual Meeting of stockholders. Dr. Schaffer will continue to serve on the Board and the Compensation Committee until his term expires at that meeting. The filing explicitly states that this decision was not the result of any disagreement with the Company.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies beyond the specific event of the director's departure.
Investor Verification Checklist
- Confirm the date of the 2018 Annual Meeting of stockholders to determine the exact end of Dr. Schaffer's term.
- Review the Company's proxy statement or subsequent filings to identify the slate of nominees for the Board of Directors.
- Verify if there are any other pending changes to the Board composition or Compensation Committee.